WUNworks

Wunworks is a biotechnology company focused on developing a new class of therapeutics that modulate the Wnt signaling pathway. Founded by world-renowned Wnt experts Roel Nusse and Yashi Ahmed, the company aims to translate decades of fundamental research into treatments for cancer, fibrosis, and degenerative diseases. The Wnt pathway is a critical regulator of cell fate, stem cell renewal, and tissue homeostasis, making it a high-value but historically challenging therapeutic target. Wunworks utilizes proprietary insights to develop precise modulators that can either activate or inhibit signaling to restore healthy tissue function. The company is currently in the pre-clinical stage and is supported by leading venture capital firms such as SR One and The Column Group.